For: | Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, Boer SY, Hartog GD, Hooymans PM, Mäkelburg AB, Westerveld BD, Naber AH, Mulder CJ, Jong DJ. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005; 11(35): 5540-5544 [PMID: 16222751 DOI: 10.3748/wjg.v11.i35.5540] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v11/i35/5540.htm |
Number | Citing Articles |
1 |
Anuraag Jena, Pardhu B Neelam, Harshavardhan Telaprolu, Uday Kiran Mangipudi, Usha Dutta, Shaji Sebastian, Vishal Sharma. Effectiveness and safety of thioguanine as a maintenance therapy of inflammatory bowel disease: Systematic review, meta-analysis and meta-regression. Clinics and Research in Hepatology and Gastroenterology 2023; 47(7): 102155 doi: 10.1016/j.clinre.2023.102155
|
2 |
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes, Adriaan A. van Bodegraven. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 2018; 57(9): 1075 doi: 10.1007/s40262-018-0639-4
|
3 |
Robin J. Dart, Peter M. Irving. Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 2017; 13(9): 877 doi: 10.1080/1744666X.2017.1351298
|
4 |
Paul Andrew Blaker, Monica Arenas-Hernandez, Anthony Marin Marinaki, Jeremy David Sanderson. The Pharmacogenetic Basis of Individual Variation in Thiopurine Metabolism. Personalized Medicine 2012; 9(7): 707 doi: 10.2217/pme.12.85
|
5 |
Miloslav Kverka, Pavel Rossmann, Helena Tlaskalova-Hogenova, Klara Klimesova, Bindia Jharap, Nanne K de Boer, Rene M Vos, Adriaan A van Bodegraven, Milan Lukas, Chris J Mulder. Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. BMC Gastroenterology 2011; 11(1) doi: 10.1186/1471-230X-11-47
|
6 |
S. Ngo, G. Sauvetre, O. Vittecoq, H. Lévesque, I. Marie. Aplasie médullaire induite par l’azathioprine : intérêt de la recherche systématique d’une mutation du gène de la thiopurine S-méthyltransférase ?. La Revue de Médecine Interne 2011; 32(6): 373 doi: 10.1016/j.revmed.2010.09.006
|
7 |
Nanne KH de Boer, Adriaan A van Bodegraven, Bindia Jharap, Peer de Graaf, Chris JJ Mulder. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nature Clinical Practice Gastroenterology & Hepatology 2007; 4(12): 686 doi: 10.1038/ncpgasthep1000
|
8 |
Albert J. Czaja. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Alimentary Pharmacology & Therapeutics 2020; 51(12): 1286 doi: 10.1111/apt.15743
|
9 |
James H Lewis, Moustafa Ahmed, Ahmed Shobassy, Caren Palese. Drug-induced liver disease. Current Opinion in Gastroenterology 2006; 22(3): 223 doi: 10.1097/01.mog.0000218958.40441.fd
|
10 |
Javier P. Gisbert, Yago González-Lama, José Maté. Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review. The American Journal of Gastroenterology 2007; 102(7): 1518 doi: 10.1111/j.1572-0241.2007.01187.x
|
11 |
Marcio L. De Paula, Fernanda G. Braga, Elaine S. Coimbra, Arturene M. L. Carmo, Henrique C. Teixeira, Adilson D. Da Silva, Maria A. Souza, Ana Paula Ferreira. Modulatory Effects of 6‐Carboxymethylthiopurine on Activated Murine Macrophages. Chemical Biology & Drug Design 2008; 71(6): 563 doi: 10.1111/j.1747-0285.2008.00665.x
|
12 |
Nanne K H de Boer, Laurent Peyrin-Biroulet, Bindia Jharap, Jeremy D Sanderson, Berrie Meijer, Imke Atreya, Murray L Barclay, Jean-Frederic Colombel, Anthony Lopez, Laurent Beaugerie, Anthony M Marinaki, Adriaan A van Bodegraven, Markus F Neurath. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis 2018; 12(5): 610 doi: 10.1093/ecco-jcc/jjx181
|
13 |
Melek Simsek, Debbie S. Deben, Carmen S. Horjus, Melanie V. Bénard, Birgit I. Lissenberg‐Witte, Hans J. C. Buiter, Matthijs van Luin, Margien L. Seinen, Chris J. J. Mulder, Dennis R. Wong, Nanne K. H. de Boer, Adriaan A. van Bodegraven. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Alimentary Pharmacology & Therapeutics 2019; 50(1): 54 doi: 10.1111/apt.15280
|
14 |
Paula Sousa, Maria Manuela Estevinho, Cláudia Camila Dias, Paula Ministro, Uri Kopylov, Silvio Danese, Laurent Peyrin-Biroulet, Fernando Magro. Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis. Journal of Clinical Medicine 2020; 9(7): 2216 doi: 10.3390/jcm9072216
|
15 |
J. -F. Colombel, M. Toruner. Immunoregulation in Inflammatory Bowel Diseases — Current Understanding and Innovation. Falk Symposium 2007; 153: 85 doi: 10.1007/978-1-4020-5889-9_10
|
16 |
Felix Braun, Matthias Behrend. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 2008; 30: 452 doi: 10.1016/S0378-6080(08)00038-X
|
17 |
Luc J.J. Derijks, Lennard P.L. Gilissen, Nanne K.H. de Boer, Chris J.J. Mulder. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: Dose or level dependent?. Journal of Hepatology 2006; 44(4): 821 doi: 10.1016/j.jhep.2005.11.049
|
18 |
Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. 2010; : 371 doi: 10.1016/B978-0-444-53273-2.50007-9
|
19 |
N.K.H. de Boer, P.E. Zondervan, L.P.L. Gilissen, G. den Hartog, B.D. Westerveld, L.J.J. Derijks, E. Bloemena, L.G.J.B. Engels, A.A. van Bodegraven, C.J.J. Mulder. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Digestive and Liver Disease 2008; 40(2): 108 doi: 10.1016/j.dld.2007.10.013
|
20 |
Melek Simsek, Berrie Meijer, Chris J. J. Mulder, Adriaan A. van Bodegraven, Nanne K. H. de Boer. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2017; 39(6): 584 doi: 10.1097/FTD.0000000000000455
|
21 |
C. O. Musumba. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Alimentary Pharmacology & Therapeutics 2013; 38(9): 1025 doi: 10.1111/apt.12490
|
22 |
L.P.L. Gilissen, L.J.J. Derijks, A. Driessen, L.P. Bos, P.M. Hooymans, R.W. Stockbrügger, L.G.J.B. Engels. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Digestive and Liver Disease 2007; 39(2): 156 doi: 10.1016/j.dld.2006.10.007
|
23 |
Roslyn Kemp, Elliott Dunn, Michael Schultz. Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents. BioDrugs 2013; 27(6): 585 doi: 10.1007/s40259-013-0045-2
|
24 |
Lennard P.L. Gilissen, Rudaba Tajzai, Marielle Romberg, Marieke Pierik, Arnold Stronkhorst, Karin Steenhuisen, Ad Van Bodegraven, Alette Daniels, Dennis Wong. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e102 doi: 10.1097/MEG.0000000000001980
|
25 |
Erik H.C.J. Buster, Hanneke J. van Vuuren, Pieter E. Zondervan, Herold J. Metselaar, Hugo W. Tilanus, Robert A. de Man. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. European Journal of Gastroenterology & Hepatology 2008; 20(1): 68 doi: 10.1097/MEG.0b013e32825a6a8a
|
26 |
Chad Best, Boris Sudel. Bone Marrow Suppression in the Setting of Normal Thiopurine Methyltransferase Phenotype Testing. Clinical Pediatrics 2010; 49(9): 901 doi: 10.1177/0009922809335739
|
27 |
E. J. M. VAN GEENEN, N. K. H. DE BOER, P. STASSEN, R. K. LINSKENS, M. J. BRUNO, C. J. J. MULDER, C. A. STEGEMAN, A. A. VAN BODEGRAVEN. Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon. Alimentary Pharmacology & Therapeutics 2010; 31(12): 1322 doi: 10.1111/j.1365-2036.2010.04287.x
|
28 |
W.G.N. Mares, D.R. Wong, L.P.L. Gilissen, A.A.M. Masclee, P.M. Hooymans, L.G.J.B. Engels. Safe 6-thioguanine therapy of a TPMT deficient Crohn's disease patient by using therapeutic drug monitoring. Journal of Crohn's and Colitis 2009; 3(2): 128 doi: 10.1016/j.crohns.2009.02.002
|
29 |
Kirstin M. Taylor, Mark G. Ward, Paul A. Blaker, Miles P. Sparrow. Is there a role for thioguanine therapy in IBD in 2017 and beyond?. Expert Review of Gastroenterology & Hepatology 2017; 11(5): 473 doi: 10.1080/17474124.2017.1294062
|
30 |
Alexander Teml, Matthias Schwab, Daan W. Hommes, Sven Almer, Milan Lukas, Thomas Feichtenschlager, Timothy Florin, Julia Seiderer, Wolfgang Petritsch, Bernd Bokemeyer, Wolfgang Kreisel, Klaus R. Herrlinger, Peter Knoflach, Bruno Bonaz, Thomas Klugmann, Hans Herfarth, Nikolaus Pedarnig, Walter Reinisch. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wiener klinische Wochenschrift 2007; 119(17-18): 519 doi: 10.1007/s00508-007-0841-0
|
31 |
S.H.C. Almer, H. Hjortswang, U. Hindorf. 6-Thioguanine therapy in Crohn′s disease—Observational data in Swedish patients. Digestive and Liver Disease 2009; 41(3): 194 doi: 10.1016/j.dld.2008.07.314
|
32 |
Pal Miheller, Peter Laszlo Lakatos. Thiopurines in Crohn's disease, is there something new?. Expert Opinion on Drug Metabolism & Toxicology 2010; 6(12): 1505 doi: 10.1517/17425255.2010.525505
|
33 |
J.K. Aronson. A worldwide yearly survey of new data in adverse drug reactions. Side Effects of Drugs Annual 2011; 33: 815 doi: 10.1016/B978-0-444-53741-6.00038-6
|
34 |
Ramya Movva, Alison Haywood, Sohil A Khan, Timothy HJ Florin, Iulia Oancea. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?. Journal of Digestive Diseases 2017; 18(9): 529 doi: 10.1111/1751-2980.12536
|